In vitro and in vivo effects of JAK2 inhibition in chronic myelomonocytic leukemia

European Journal of Haematology

Volumn 97, Issue 6, 2016, Pages 562-567

  Geissler, Klaus ^a   Jäger, Eva ^b   Barna, Agnes ^c   Sliwa, Thamer ^d   Knöbl, Paul ^b   Schwarzinger, Ilse ^b   Gisslinger, Heinz ^b   Valent, Peter ^b  

^a Neurological Center Rosenhuegel   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c Red Cross Blood Transfusion Service of Upper Austria   (Austria)

^d HANUSCH HOSPITAL   (Austria)

Author keywords

chronic myelomonocytic leukemia; colony forming units granulocyte macrophage; JAK2 inhibition; ruxolitinib

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; JANUS KINASE 2; JANUS KINASE 2 INHIBITOR; N TERT BUTYL 3 [5 METHYL 2 [4 (4 METHYL 1 PIPERAZINYL)PHENYLAMINO] 4 PYRIMIDINYLAMINO]BENZENESULFONAMIDE; RUXOLITINIB; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR; PYRAZOLE DERIVATIVE;

ADULT; AGED; ARTICLE; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL ARTICLE; COLONY FORMING UNIT GM; CONTROLLED STUDY; DRUG DESIGN; DRUG EFFECT; DRUG INHIBITION; ENZYME INHIBITION; EX VIVO STUDY; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; MACROPHAGE; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SPLENOMEGALY; VERY ELDERLY; ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; CFU COUNTING; DOSE RESPONSE; DRUG EFFECTS; GENETICS; LEUKEMIA, MYELOMONOCYTIC, CHRONIC; METABOLISM; MIDDLE AGED; MUTATION; X-RAY COMPUTED TOMOGRAPHY;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; COLONY-FORMING UNITS ASSAY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GRANULOCYTE-MACROPHAGE PROGENITOR CELLS; HUMANS; JANUS KINASE 2; LEUKEMIA, MYELOMONOCYTIC, CHRONIC; MALE; MIDDLE AGED; MUTATION; PROTEIN KINASE INHIBITORS; PYRAZOLES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84994318967     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/ejh.12773     Document Type: Article

References (19)

1. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009;114:937–51.
2. Germing U, Strupp C, Knipp S, Kuendgen A, Giagounidis A, Hildebrandt B, Aul C, Haas R, Gattermann N, Bennett JM. Chronic myelomonocytic leukemia in the light of the WHO proposals. Haematologica 2007;92:974–7.
3. Geissler K, Hinterberger W, Bettelheim P, Haas O, Lechner K. Colony growth characteristics in chronic myelomonocytic leukemia. Leuk Res 1988;12:373–7.
4. Geissler K, Ohler L, Födinger M, et al. Interleukin 10 inhibits growth and granulocyte/macrophage colony-stimulating factor production in chronic myelomonocytic leukemia cells. J Exp Med 1996;184:1377–84.
5. Sagaster V, Ohler L, Berer A, Kabrna E, Ofner P, Lechner K, Geissler K. High spontaneous colony growth in chronic myelomonocytic leukemia correlates with increased disease activity and is a novel prognostic factor for predicting short survival. Ann Hematol 2004;83:9–13.
6. Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012;366:799–807.
7. Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 2012;366:787–98.
8. Mascarenhas J, Mughal TI, Verstovsek S. Biology and clinical management of myeloproliferative neoplasms and development of the JAK inhibitor ruxolitinib. Curr Med Chem 2012;19:4399–413.
9. Padron E, Painter JS, Kunigal S, et al. GM-CSF-dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia. Blood 2013;121:5068–77.
10. Hansen G, Hercus TR, McClure BJ, et al. The structure of the GM-CSF receptor complex reveals a distinct mode of cytokine receptor activation. Cell 2008;134:496–507.
11. Pardanani A, Hood J, Lasho T, et al. TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations. Leukemia 2007;21:1658–68.
12. Geissler K, Peschel C, Niederwieser D, et al. Potentiation of granulocyte colony-stimulating factor-induced mobilization of circulating progenitor cells by seven-day pretreatment with interleukin-3. Blood 1996;87:2732–9.
13. Oehler L, Foedinger M, Koeller M, Kollars M, Reiter E, Bohle B, Skoupy S, Fritsch G, Lechner K, Geissler K. Interleukin-10 inhibits spontaneous colony-forming unit-granulocyte-macrophage growth from human peripheral blood mononuclear cells by suppression of endogenous granulocyte-macrophage colony-stimulating factor release. Blood 1997;89:1147–53.
14. Parganas E, Wang D, Stravopodis D, et al. Jak2 is essential for signaling through a variety of cytokine receptors. Cell 1998;93:385–95.
15. Ricci C, Fermo E, Corti S, Molteni M, Faricciotti A, Cortelezzi A, Lambertenghi Deliliers G, Beran M, Onida F. RAS mutations contribute to evolution of chronic myelomonocytic leukemia to the proliferative variant. Clin Cancer Res 2010;16:2246–56.
16. Zhang J, Ranheim EA, Du J, Liu Y, Wang J, Kong G, Zhang J. Deficiency of β common receptor moderately attenuates the progression of myeloproliferative neoplasm in NrasG12D/+ mice. J Biol Chem 2015;290:19093–103.
17. Kotecha N, Flores NJ, Irish JM, et al. Single-cell profiling identifies aberrant STAT5 activation in myeloid malignancies with specific clinical and biologic correlates. Cancer Cell 2008;14:335–43.
18. Kong G, Wunderlich M, Yang D, et al. MEK and JAK inhibition abrogates murine myeloproliferative neoplasm. J Clin Invest 2014;124:2762–73.
19. Prassopoulos P, Daskalogiannaki M, Raissaki M, Hatjidakis A, Gourtsoyiannis N. Determination of normal splenic volume on computed tomography in relation to age, gender and body habitus. Eur Radiol 1997;7:246–8.